News

  • 6 December 2018

    AbbVie halts phase III TAHOE trial of Rova-T for SCLC

    Following advice from an independent data monitoring committee, biopharma company AbbVie has ceased enrolment in its TAHOE trial evaluating Rovalpituzumab Tesirine (Rova-T) as a second line therapy for patients with...

Go Top